Nathan Van Bibber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nathan Van Bibber has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Anna E. Coghill
Cancer Epidemiology Program, Division of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
11 shared publications - Gita Suneja
Department of Radiation Oncology, University of Utah School of Medicine, Huntsman Cancer Institute , Salt Lake City, Utah
9 shared publications - Adam Mitchell Spivak
Division of Infectious Diseases, Department of Internal Medicine, Huntsman Cancer Institute – University of Utah, Salt Lake City, Utah
5 shared publications - Alex C. Soupir
Moffitt Cancer Center
5 shared publications - Beatrice S. Knudsen
University of Utah
5 shared publications - Carlos Moran Segura
Advanced Analytical and Digital Laboratory, Moffitt Cancer Center, Tampa, Florida
5 shared publications
Latest Publications
- 29 July 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 313
Clinical characteristics and outcomes of melanoma and non-melanoma skin cancers in persons living with HIV
- 29 July 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 313
Clinical characteristics and outcomes of melanoma and non-melanoma skin cancers in persons living with HIV
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 2: Number of Tumor Samples, and Number (%) Individual Patients, with Tissue Staining Results Available, by Immune Marker and Cancer Type.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 2: Number of Tumor Samples, and Number (%) Individual Patients, with Tissue Staining Results Available, by Immune Marker and Cancer Type.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Figure 1: Percentage of tumor cells staining positive for immune markers, and age and race-adjusted associations (ORs [95% CI]) between tumor immune marker staining abundance and patient HIV status, by cancer type. All immune markers associations are shown.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Figure 1: Percentage of tumor cells staining positive for immune markers, and age and race-adjusted associations (ORs [95% CI]) between tumor immune marker staining abundance and patient HIV status, by cancer type. All immune markers associations are shown.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 1: Number of Study Specimens by HIV Status, Cancer Type, and Source.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 1: Number of Study Specimens by HIV Status, Cancer Type, and Source.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background:Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction.Methods:Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus.Results:A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c.Conclusions:This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed.Impact:Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background:Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction.Methods:Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus.Results:A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c.Conclusions:This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed.Impact:Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1. from Elevated Tumor Mutation Burden in Cancer Patients with Underlying HIV Infection: Data from the Oncology Research Information Exchange Network (ORIEN)
Supplemental Figure 1. Average proportion of tumor-specific mutations classified as putative class I neoantigens, according to HIV status and cancer site. Statistical comparisons (p-values) were computed using a Wilcoxon test.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1. from Elevated Tumor Mutation Burden in Cancer Patients with Underlying HIV Infection: Data from the Oncology Research Information Exchange Network (ORIEN)
Supplemental Figure 1. Average proportion of tumor-specific mutations classified as putative class I neoantigens, according to HIV status and cancer site. Statistical comparisons (p-values) were computed using a Wilcoxon test.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Elevated Tumor Mutation Burden in Cancer Patients with Underlying HIV Infection: Data from the Oncology Research Information Exchange Network (ORIEN)
Supplemental Table 1: Average genomic features by cancer patient HIV status, listed by cancer site
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Elevated Tumor Mutation Burden in Cancer Patients with Underlying HIV Infection: Data from the Oncology Research Information Exchange Network (ORIEN)
Supplemental Table 1: Average genomic features by cancer patient HIV status, listed by cancer site
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Data from Elevated Tumor Mutation Burden in Cancer Patients with Underlying HIV Infection: Data from the Oncology Research Information Exchange Network (ORIEN)
Background:People living with HIV (PWH) have improved life expectancy because of effective human immunodeficiency virus (HIV) therapy but still experience immune impairment (e.g., altered CD4/CD8 T cells). We hypothesized that tumors diagnosed in PWH would have distinct molecular features.Methods:We utilized whole-exome sequencing of paired tumor and germline DNA and RNA from 229 patients with cancer enrolled into the Oncology Research Information Exchange Network to classify total tumor mutation burden (TMB), MHC class I neoantigen count, and MHC class II neoantigen count.Results:Specimens from 229 patients with cancer (110 PWH and 119 without HIV) were evaluated. Average TMB for tumors diagnosed in PWH was 249, compared with 172 for those without HIV. After adjustment for age, sex, race, smoking, and cancer site, the association between HIV and TMB remained statistically significant (OR = 1.72; 95% confidence interval (CI), 1.26–2.43). We further observed an association between HIV and higher putative class I neoantigen count (OR = 1.62; 95% CI, 1.10–2.41) but no association with putative class II neoantigens. When considering cancer sites separately in unadjusted analyses, average TMB was elevated in PWH for thyroid (P < 0.01) and bladder cancers (P = 0.03) and sarcoma (P = 0.04). Similarly, putative class I neoantigen count was elevated in PWH for head and neck (P < 0.01) and thyroid (P = 0.01) cancers, as well as sarcoma (P = 0.04).Conclusions:Our findings indicate that tumors diagnosed in PWH harbor a higher TMB and a higher number of putative class I neoantigens.Impact:A higher TMB in PWH may portend a more favorable response to certain cancer treatment modalities such as immune checkpoint inhibitors.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Elevated Tumor Mutation Burden in Cancer Patients with Underlying HIV Infection: Data from the Oncology Research Information Exchange Network (ORIEN)
Background:People living with HIV (PWH) have improved life expectancy because of effective human immunodeficiency virus (HIV) therapy but still experience immune impairment (e.g., altered CD4/CD8 T cells). We hypothesized that tumors diagnosed in PWH would have distinct molecular features.Methods:We utilized whole-exome sequencing of paired tumor and germline DNA and RNA from 229 patients with cancer enrolled into the Oncology Research Information Exchange Network to classify total tumor mutation burden (TMB), MHC class I neoantigen count, and MHC class II neoantigen count.Results:Specimens from 229 patients with cancer (110 PWH and 119 without HIV) were evaluated. Average TMB for tumors diagnosed in PWH was 249, compared with 172 for those without HIV. After adjustment for age, sex, race, smoking, and cancer site, the association between HIV and TMB remained statistically significant (OR = 1.72; 95% confidence interval (CI), 1.26–2.43). We further observed an association between HIV and higher putative class I neoantigen count (OR = 1.62; 95% CI, 1.10–2.41) but no association with putative class II neoantigens. When considering cancer sites separately in unadjusted analyses, average TMB was elevated in PWH for thyroid (P < 0.01) and bladder cancers (P = 0.03) and sarcoma (P = 0.04). Similarly, putative class I neoantigen count was elevated in PWH for head and neck (P < 0.01) and thyroid (P = 0.01) cancers, as well as sarcoma (P = 0.04).Conclusions:Our findings indicate that tumors diagnosed in PWH harbor a higher TMB and a higher number of putative class I neoantigens.Impact:A higher TMB in PWH may portend a more favorable response to certain cancer treatment modalities such as immune checkpoint inhibitors.
- 4 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (6) , 860-867
Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background: Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction. Methods: Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus. Results: A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c. Conclusions: This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed. Impact: Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- 4 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (6) , 860-867
Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background: Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction. Methods: Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus. Results: A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c. Conclusions: This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed. Impact: Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- Open Access
- 28 March 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (7) , 1658-1669
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas
Epstein-Barr virus (EBV) is associated with a diverse range of lymphomas. EBV-specific T-cell (EBVST) infusions have shown promise in safety and clinical effectiveness in treating EBV-associated lymphomas; however, not all patients respond to T-cell immunotherapies. To identify EBV antigen–specific antibody responses associated with clinical outcomes, we comprehensively characterized antibody responses to the complete EBV proteome using a custom protein microarray in 56 patients with EBV-associated lymphoma who received EBVST infusions in phase 1 clinical trials. Responders (nonprogressors) and nonresponders (progressors) had distinct antibody profiles against EBV. Twenty-five immunoglobulin G (IgG) antibodies were significantly elevated in higher levels in nonresponders than in responders at 3 months after EBVST infusion. Ten of these remained significant after adjustment for sex, age, and cancer type, including LMP2A (4 variants), BGRF1/BDRF1 (2 variants), LMP1, BKRF2, BKRF4, and BALF5. Random forest analysis identified these 10 IgG antibodies as key predictors of clinical response. Paired analyses using blood samples collected at both before infusion and 3 months after EBVST infusion indicated an increase in the mean antibody level for 6 other anti-EBV antibodies (IgG [BGLF2, LF1, and BGLF3]; IgA [BGLF3, BALF2, and BBLF2/3) in nonresponders. Overall, our findings suggest that these EBV-directed antibodies as potential serological markers for predicting clinical responses to EBVST infusions and as therapeutic targets for immunotherapy in EBV-positive lymphomas. These trials were registered at www.clinicaltrials.gov as #NCT01555892 (Cytotoxic T-Lymphocytes for EBV-positive Lymphoma [GRALE]), #NCT02973113 (Nivolumab With Epstein Barr Virus Specific T Cells [EBVSTS], Relapsed/Refractory EBV Positive Lymphoma [PREVALE]), and #NCT02287311 (Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1, and EBNA1 Specific CTL, EBV-Positive Lymphoma [MABEL]).
- 28 March 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (7) , 1658-1669
Open AccessDifferential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas
Epstein-Barr virus (EBV) is associated with a diverse range of lymphomas. EBV-specific T-cell (EBVST) infusions have shown promise in safety and clinical effectiveness in treating EBV-associated lymphomas; however, not all patients respond to T-cell immunotherapies. To identify EBV antigen–specific antibody responses associated with clinical outcomes, we comprehensively characterized antibody responses to the complete EBV proteome using a custom protein microarray in 56 patients with EBV-associated lymphoma who received EBVST infusions in phase 1 clinical trials. Responders (nonprogressors) and nonresponders (progressors) had distinct antibody profiles against EBV. Twenty-five immunoglobulin G (IgG) antibodies were significantly elevated in higher levels in nonresponders than in responders at 3 months after EBVST infusion. Ten of these remained significant after adjustment for sex, age, and cancer type, including LMP2A (4 variants), BGRF1/BDRF1 (2 variants), LMP1, BKRF2, BKRF4, and BALF5. Random forest analysis identified these 10 IgG antibodies as key predictors of clinical response. Paired analyses using blood samples collected at both before infusion and 3 months after EBVST infusion indicated an increase in the mean antibody level for 6 other anti-EBV antibodies (IgG [BGLF2, LF1, and BGLF3]; IgA [BGLF3, BALF2, and BBLF2/3) in nonresponders. Overall, our findings suggest that these EBV-directed antibodies as potential serological markers for predicting clinical responses to EBVST infusions and as therapeutic targets for immunotherapy in EBV-positive lymphomas. These trials were registered at www.clinicaltrials.gov as #NCT01555892 (Cytotoxic T-Lymphocytes for EBV-positive Lymphoma [GRALE]), #NCT02973113 (Nivolumab With Epstein Barr Virus Specific T Cells [EBVSTS], Relapsed/Refractory EBV Positive Lymphoma [PREVALE]), and #NCT02287311 (Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1, and EBNA1 Specific CTL, EBV-Positive Lymphoma [MABEL]).